284 patients included in the BioCer trial

We've reached a significant milestone by enrolling all 284 patients in our randomized clinical trial, BioCer. With all necessary participants onboard, we are now focused on completing the trial and advancing our research efforts to improve patient outcomes and understand treatment efficacy.

The clinical trial on Cerebri is progressing well, with the inclusion of the final patients marking a significant advancement in our efforts to improve healthcare practices and patient well-being. This collaborative endeavor, involving NTNU, NorHEAD, St. Olavs Hospital, Akershus Universitetssykehus, Haukeland Universitetssykehus, and sponsored by Nordic Brain Tech AS, is focused on exploring innovative approaches to treating migraine with home-based biofeedback.

Funded by Nordic Brain Tech, NTNU, NorHEAD, the Regional Research Fund Oslo, and Eureka's Eurostars program (E! 115549 - CEREBRI), this trial underscores the crucial role of interdisciplinary collaboration and financial support in driving medical research forward. It demonstrates the commitment of various stakeholders to advancing scientific knowledge and translating it into tangible benefits for patients.

The primary objective of the trial is to assess the comparative effectiveness of home-based biofeedback in treating migraine.

As we continue with the BioCer trial, we remain committed to upholding the highest standards of scientific rigor and ethical conduct. Patient safety and well-being are prioritized, with strict adherence to established protocols and guidelines throughout the trial duration.